Modifications by sumatriptan and acetylcholine of nitric oxide-mediated neurogenic dilatation in dog cerebral arteries

被引:8
作者
Ayajiki, K
Fujioka, H
Noda, K
Okamura, T
Toda, N [1 ]
机构
[1] Nippon Shinyaku Co Ltd, Res Labs, Minami Ku, Kyoto 6018550, Japan
[2] Shiga Univ Med Sci, Dept Pharmacol, Otsu, Shiga 5202192, Japan
关键词
sumatriptan; acetylcholine; nitroxidergic nerve; nitrergic; cerebral artery;
D O I
10.1016/S0014-2999(01)01019-6
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
Canine cerebral arterial strips denuded of endothelium responded to nicotine and transmural electrical stimulation with relaxations, which were abolished by NG-nitro-L-arginine and methylene blue. Magnitudes of relaxation did not differ in the arteries contracted with prostaglandin F2 alpha and sumatriptan, an effective therapeutic of migraine. Sumatriptan concentration-dependently contracted the arteries responding to 2 Hz stimulation with persistent relaxations, and the concentration of this 5-HT1B/(1D)/(1F) receptor agonist to overcome the relaxation averaged 1.06 x 10(-7) M. Acetylcholine inhibited the response to nerve stimulation due possibly to its action on prejunctional nitroxidergic nerves; the inhibition did not differ in the arteries contracted with prostaglandin F-2 alpha and K+. It appears that sumatriptan does not interfere with the release of nitric oxide from nerves but counteracts the neurogenic relaxation by functional antagonistic action on smooth muscle. Prejunctional inhibition by muscarinic receptor activation is unlikely associated with opening of neuronal K+ channels. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:67 / 72
页数:6
相关论文
共 36 条
[1]
HEADACHE PROVOCATION BY CONTINUOUS INTRAVENOUS-INFUSION OF HISTAMINE - CLINICAL-RESULTS AND RECEPTOR MECHANISMS [J].
AEBELHOLTKRABBE, A ;
OLESEN, J .
PAIN, 1980, 8 (02) :253-259
[2]
Involvement of CYP3A-derived arachidonic acid metabolite(s) in responses to endothelium-derived KC channel opening substance in monkey lingual artery [J].
Ayajiki, K ;
Okamura, T ;
Fujioka, H ;
Imaoka, S ;
Funae, Y ;
Toda, N .
BRITISH JOURNAL OF PHARMACOLOGY, 1999, 128 (03) :802-808
[3]
Flunarizine, an anti-migraine agent, impairs nitroxidergic nerve function in cerebral arteries [J].
Ayajiki, K ;
Okamura, T ;
Toda, N .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 329 (01) :49-53
[4]
AN INHIBITORY PREJUNCTIONAL 5-HT1-LIKE RECEPTOR IN THE ISOLATED PERFUSED RAT-KIDNEY - APPARENT DISTINCTION FROM THE 5-HT1A, 5-HT1B AND 5-HT1C SUBTYPES [J].
CHARLTON, KG ;
BOND, RA ;
CLARKE, DE .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1986, 332 (01) :8-15
[5]
CLINICAL AND EXPERIMENTAL EFFECTS OF SUMATRIPTAN IN HUMANS [J].
FERRARI, MD ;
SAXENA, PR .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1993, 14 (04) :129-133
[6]
MIGRAINE PAIN ASSOCIATED WITH MIDDLE CEREBRAL-ARTERY DILATATION - REVERSAL BY SUMATRIPTAN [J].
FRIBERG, L ;
OLESEN, J ;
IVERSEN, HK ;
SPERLING, B .
LANCET, 1991, 338 (8758) :13-17
[7]
FURCHGOTT R F, 1988, P401
[8]
THE TRIGEMINOVASCULAR SYSTEM AND MIGRAINE - STUDIES CHARACTERIZING CEREBROVASCULAR AND NEUROPEPTIDE CHANGES SEEN IN HUMANS AND CATS [J].
GOADSBY, PJ ;
EDVINSSON, L .
ANNALS OF NEUROLOGY, 1993, 33 (01) :48-56
[9]
Alignment of receptor nomenclature with the human genome: Classification of 5-HT1B and 5-HT1D receptor subtypes [J].
Hartig, PR ;
Hoyer, D ;
Humphrey, PPA ;
Martin, GR .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1996, 17 (03) :103-105
[10]
MODE OF ACTION OF THE ANTIMIGRAINE DRUG SUMATRIPTAN [J].
HUMPHREY, PPA ;
FENIUK, W .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1991, 12 (12) :444-446